NCT04098861

Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma

Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Universiti Kebangsaan Malaysia Medical Centre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is constantly associated with progression of visual field loss. Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It is a known fact that glaucoma patients often require addition of a second antiglaucoma medications when disease progresses or tachyphylaxis occurs. It was reported that more than 50% of patients require 2 or more medications to achieve optimum IOP control. Nevertheless, compliance and adherence are often impaired with multiple-drug therapy. Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic regimen by reducing the number of medications used and the total number of doses administered.

Conditions

• Primary Open Angle Glaucoma

Interventions

Type	Name	Description
DRUG	Latanoprost/Timolol	Latanoprost/Timolol Fixed Combination

Timeline

• Start date: 2019-01-02
• Primary completion: 2020-08-31
• Completion: 2020-12-01
• First posted: 2019-09-23
• Last updated: 2019-09-23

Locations

1 site across 1 country: Malaysia

Regulatory

• FDA-regulated drug study